Clinical Trials Directory

Trials / Completed

CompletedNCT00386009

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Eli Lilly and Company · Industry
Sex
Male
Age
40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.

Conditions

Interventions

TypeNameDescription
DRUGTadalafil20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
DRUGPlaceboPlacebo tablet taken by mouth once a day for 12 weeks.

Timeline

Start date
2006-10-01
Primary completion
2008-05-01
Completion
2008-05-01
First posted
2006-10-11
Last updated
2009-07-09
Results posted
2009-06-23

Locations

13 sites across 3 countries: United States, Greece, Portugal

Source: ClinicalTrials.gov record NCT00386009. Inclusion in this directory is not an endorsement.

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (NCT00386009) · Clinical Trials Directory